M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
bluebird bio Inc admits first patient in Phase 1/2 HGB-205 study of beta-thalassemia major and sickle cell disease
Gene therapies company bluebird bio Inc (NasdaqGS:BLUE) said on Monday that its first subject with beta-thalassemia major has been enrolled in its phase 1/2 HGB-205 study in France.
The company added that the patient has undergone infusion with its LentiGlobin drug product in an autologous...
If you want to view the full text, you must first purchase archive credits.
Return to Archives